Cargando…
[(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections
BACKGROUND: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant st...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385282/ https://www.ncbi.nlm.nih.gov/pubmed/25853019 http://dx.doi.org/10.1186/s13550-015-0095-1 |
_version_ | 1782365038636433408 |
---|---|
author | Mills, Bethany Awais, Ramla O Luckett, Jeni Turton, Dave Williams, Paul Perkins, Alan C Hill, Philip J |
author_facet | Mills, Bethany Awais, Ramla O Luckett, Jeni Turton, Dave Williams, Paul Perkins, Alan C Hill, Philip J |
author_sort | Mills, Bethany |
collection | PubMed |
description | BACKGROUND: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant strains including methicillin-resistant S. aureus (MRSA). Fluorodeoxyglucose ([(18)F]FDG) imaging has been used to identify infection sites; however, it is unable to distinguish between sterile inflammation and bacterial load. We have modified [(18)F]FDG by phosphorylation, producing [(18)F]FDG-6-P to facilitate specific uptake and accumulation by S. aureus through hexose phosphate transporters, which are not present in mammalian cell membranes. This approach leads to the specific uptake of the radiopharmaceutical into the bacteria and not the sites of sterile inflammation. METHODS: [(18)F]FDG-6-P was synthesised from [(18)F]FDG. Yield, purity and stability were confirmed by RP-HPLC and iTLC. The specificity of [(18)F]FDG-6-P for the bacterial universal hexose phosphate transporter (UHPT) was confirmed with S. aureus and mammalian cell assays in vitro. Whole body biodistribution and accumulation of [(18)F]FDG-6-P at the sites of bioluminescent staphylococcal infection were established in a murine foreign body infection model. RESULTS: In vitro validation assays demonstrated that [(18)F]FDG-6-P was stable and specifically transported into S. aureus but not mammalian cells. [(18)F]FDG-6-P was elevated at the sites of S. aureus infection in vivo compared to uninfected controls; however, the increase in signal was not significant and unexpectedly, the whole-body biodistribution of [(18)F]FDG-6-P was similar to that of [(18)F]FDG. CONCLUSIONS: Despite conclusive in vitro validation, [(18)F]FDG-6-P did not behave as predicted in vivo. However at the site of known infection, [(18)F]FDG-6-P levels were elevated compared with uninfected controls, providing a higher signal-to-noise ratio. The bacterial UHPT can transport hexose phosphates other than glucose, and therefore alternative sugars may show differential biodistribution and provide a means for specific bacterial detection. |
format | Online Article Text |
id | pubmed-4385282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-43852822015-04-07 [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections Mills, Bethany Awais, Ramla O Luckett, Jeni Turton, Dave Williams, Paul Perkins, Alan C Hill, Philip J EJNMMI Res Original Research BACKGROUND: Management of infection is a major clinical problem. Staphylococcus aureus is a Gram-positive bacterium which colonises approximately one third of the adult human population. Staphylococcal infections can be life-threatening and are frequently complicated by multi-antibiotic resistant strains including methicillin-resistant S. aureus (MRSA). Fluorodeoxyglucose ([(18)F]FDG) imaging has been used to identify infection sites; however, it is unable to distinguish between sterile inflammation and bacterial load. We have modified [(18)F]FDG by phosphorylation, producing [(18)F]FDG-6-P to facilitate specific uptake and accumulation by S. aureus through hexose phosphate transporters, which are not present in mammalian cell membranes. This approach leads to the specific uptake of the radiopharmaceutical into the bacteria and not the sites of sterile inflammation. METHODS: [(18)F]FDG-6-P was synthesised from [(18)F]FDG. Yield, purity and stability were confirmed by RP-HPLC and iTLC. The specificity of [(18)F]FDG-6-P for the bacterial universal hexose phosphate transporter (UHPT) was confirmed with S. aureus and mammalian cell assays in vitro. Whole body biodistribution and accumulation of [(18)F]FDG-6-P at the sites of bioluminescent staphylococcal infection were established in a murine foreign body infection model. RESULTS: In vitro validation assays demonstrated that [(18)F]FDG-6-P was stable and specifically transported into S. aureus but not mammalian cells. [(18)F]FDG-6-P was elevated at the sites of S. aureus infection in vivo compared to uninfected controls; however, the increase in signal was not significant and unexpectedly, the whole-body biodistribution of [(18)F]FDG-6-P was similar to that of [(18)F]FDG. CONCLUSIONS: Despite conclusive in vitro validation, [(18)F]FDG-6-P did not behave as predicted in vivo. However at the site of known infection, [(18)F]FDG-6-P levels were elevated compared with uninfected controls, providing a higher signal-to-noise ratio. The bacterial UHPT can transport hexose phosphates other than glucose, and therefore alternative sugars may show differential biodistribution and provide a means for specific bacterial detection. Springer Berlin Heidelberg 2015-03-19 /pmc/articles/PMC4385282/ /pubmed/25853019 http://dx.doi.org/10.1186/s13550-015-0095-1 Text en © Mills et al.; licensee Springer. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Original Research Mills, Bethany Awais, Ramla O Luckett, Jeni Turton, Dave Williams, Paul Perkins, Alan C Hill, Philip J [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections |
title | [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections |
title_full | [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections |
title_fullStr | [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections |
title_full_unstemmed | [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections |
title_short | [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections |
title_sort | [(18)f]fdg-6-p as a novel in vivo tool for imaging staphylococcal infections |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385282/ https://www.ncbi.nlm.nih.gov/pubmed/25853019 http://dx.doi.org/10.1186/s13550-015-0095-1 |
work_keys_str_mv | AT millsbethany 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections AT awaisramlao 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections AT luckettjeni 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections AT turtondave 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections AT williamspaul 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections AT perkinsalanc 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections AT hillphilipj 18ffdg6pasanovelinvivotoolforimagingstaphylococcalinfections |